A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate the Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With a Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age.
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Sanofi Pasteur
Most Recent Events
- 03 Jan 2025 Planned End Date changed from 30 Jul 2025 to 24 Jun 2025.
- 03 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2024 Status changed from not yet recruiting to recruiting.